Revision of PRECAUTIONS
Rosuvastatin calcium

June 3, 2014

Non-proprietary Name
Rosuvastatin calcium

Safety measure
Precautions section should be revised in a package insert.

In Clinically significant adverse reactions subsection of Adverse Reactions section, the following texts should be added (underlined parts are revised):

Erythema multiforme:
Erythema multiforme may occur. Patients should be carefully monitored, and if any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.

Peripheral nerve disorder:
Peripheral nerve disorders including sensory disturbance (such as hypoesthesia or numbness), pain or muscular weakness may occur in limbs. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.